The treatment of pulmonary Wangiella dermatitidis infection with oral voriconazole

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 3, 2011, Pages 433-436

  Bulloch, M N ^a,b  

^a CHARLESTON AREA MEDICAL CENTER   (United States)

^b University Medical Center   (United States)

Author keywords

fungi; infection; pulmonary; voriconazole; Wangiella dermatitidis

Indexed keywords

ANTIBIOTIC AGENT; VORICONAZOLE;

AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LUNG BIOPSY; LUNG INFECTION; PHAEOHYPHOMYCOSIS; SURVIVAL RATE; THORAX RADIOGRAPHY;

ADMINISTRATION, ORAL; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; EXOPHIALA; FEMALE; HUMANS; LUNG DISEASES, FUNGAL; PYRIMIDINES; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 79955780723     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01214.x     Document Type: Article

References (22)

1. Matsumoto T, Padhye AA, Ajello L, (1987) Medical significance of the so-called black yeasts. European Journal of Epidemiology, 3, 87-95.
2. Hohl PE, Holley HP, Prevost E, et al. (1983) Infectious due to Wangiella dermatitidis in humans: report of the first documented case from the United States and a review of the literature. Reviews of Infectious Diseases, 5, 854-864.
3. Kenney RT, Kwon-Chung KJ, Waytes AT, et al. (1992) Successful treatment of systemic Exophiala dermatitidis infection in a patient with chronic granulomatous disease. Clinical Infectious Diseases, 14, 235-242.
4. Silveira F, Nucci M, (2001) Emergence of black moulds in fungal disease: epidemiology and therapy. Current Opinion in Infectious Diseases, 14, 679-684. (Pubitemid 33141187)
5. Taj-Aldeen SJ, El Shafie S, Alsoub H, et al. (2006) Isolation of Exophiala dermatitidis from endotracheal aspirate of a cancer patient. Mycoses, 49, 504-509. (Pubitemid 44511103)
6. Sunhadham M, Sihanonth P, Sivichai S, et al. (2008) The neurotropic black yeast Exophiala dermatitidis has a possible origin in the tropical rain forest. Studies in Mycology, 61, 145-155.
7. Horré R, Schaal KP, Siekmeier R, et al. (2004) Isolation of fungi, especially Exophiala dermatitidis, in patients suffering from cystic fibrosis, a prospective study. Respiration, 71, 360-366. (Pubitemid 39179171)
8. Revankar SG, Patterson JE, Sutton DA, et al. (2002) Disseminated phaeohyphomycosis: review of an emerging mycosis. Clinical Infectious Diseases, 34, 467-476. (Pubitemid 34121028)
9. Barenfanger J, Ramirez F, Tewari RP, et al. (1989) Pulmonary phaeohyphomycosis in a patient with hemoptysis. Chest, 95, 1158-1160. (Pubitemid 19137028)
10. Mukaino T, Koga T, Oshita Y, et al. (2006) Exophiala dermatitidis infection in non-cystic fibrosis bronchiectasis. Respiratory Medicine, 100, 2069-2071. (Pubitemid 44490291)
11. Nachman S, Alpan O, Malowitz R, et al. (1996) Catheter-associated fungemia due to Wangiella (Exophiala dermatitidis). Journal of Clinical Microbiology, 34, 1011-1013. (Pubitemid 26091532)
12. Myoken Y, Sugata T, Fujita Y, et al. (2003) Successful treatment of invasive stomatitis due to Exophiala dermatitidis in a patient with acute myeloid leukemia. Journal of Oral Pathology and Medicine, 32, 51-54. (Pubitemid 36603934)
13. Zeng JS, Sutton DA, Fothergill AW, et al. (2007) Spectrum of clinically relevant exophiala species in the United States. Journal of Clinical Microbiology, 45, 3713-3720. (Pubitemid 350156871)
14. Diemert D, Kunimoto D, Sand C, et al. (2001) Sputum isolation of Wangiella dermatitidis in patients with cystic fibrosis. Scandinavian Journal of Infectious Diseases, 33, 777-779. (Pubitemid 33041124)
15. Griffard AE, Guajardo JR, Cooperstock MS, et al. (2010) Isolation of Exophiala dermatitidis from pigmented sputum in a cystic fibrosis patient. Pediatric Pulmonology, 45, 508-510.
16. Haase G, Skopnik H, Kusenbach G, (1990) Exophiala dermatitidis infection in cystic fibrosis. Lancet, 336, 188-189. (Pubitemid 20225031)
17. Kusenbach G, Skopnik H, Haase G, et al. (1992) Exophiala dermatitidis pneumonia in cystic fibrosis. European Journal of Pediatrics, 151, 344-346.
18. Revankar SG, (2006) Phaeohyphomycosis. Infectious Disease Clinics of North America, 20, 609-620. (Pubitemid 44389927)
19. Espinel-Ingroff A, Johnson E, Hockey H, et al. (2008) Activities of voriconazole, itraconazole, and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. Journal of Antimicrobial Chemotherapy, 61, 616-620. (Pubitemid 351321136)
20. Radford SA, Johnson EM, Warnock DW, (1997) In vitro studies of activity of voriconazole (UK-109, 496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrobial Agents and Chemotherapy, 41, 841-843. (Pubitemid 27150543)
21. Perfect JR, Marr KA, Walsh TJ, et al. (2003) Voriconazole treatment for less-common emerging, or refractory fungal infections. Clinical Infectious Diseases, 36, 1122-1131. (Pubitemid 36549632)
22. Pfizer, (2008) Vfend® (Voriconazole). New York, United States: US Physician Prescribing Information.